论文部分内容阅读
目的:观察依达拉奉联合尤瑞克林治疗急性脑梗死的疗效,以及对患者C反应蛋白(CRP)、神经功能缺损评分(NIHSS)的影响。方法:88例急性脑梗死患者随机分为观察组和对照组。对照组予依达拉奉及常规阿司匹林、阿托伐他汀治疗,观察组在对照组基础上加用尤瑞克林。对比两组患者治疗前及治疗后第7天、第14天的CRP水平及NIHSS评分,比较两组患者治疗后3月的临床疗效及治疗后的药品不良反应发生率。结果:两组患者治疗后第7天、第14天CRP水平与NIHSS评分均有显著下降(P<0.01);且观察组治疗后第7天、第14天的CRP水平与NIHSS评分均显著低于对照组(P<0.01)。观察组临床总有效率为93.18%,明显高于对照组的88.63%(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:依达拉奉联合尤瑞克林治疗急性脑梗死疗效优于单用依达拉奉,可改善患者预后,值得临床推广。
Objective: To observe the curative effect of edaravone combined with norepinephrine on acute cerebral infarction and its effect on C reactive protein (CRP) and neurological deficit score (NIHSS). Methods: 88 patients with acute cerebral infarction were randomly divided into observation group and control group. The control group was given edaravone and routine aspirin, atorvastatin treatment, the observation group in the control group based on the use of uracil. The CRP level and NIHSS score were compared between the two groups before treatment and on the 7th and 14th day after treatment. The clinical efficacy and incidence of adverse drug reactions after treatment were compared between the two groups. Results: CRP levels and NIHSS scores decreased significantly on the 7th and 14th days after treatment in both groups (P <0.01). CRP levels and NIHSS scores on the 7th and 14th days after treatment in the observation group were significantly lower In the control group (P <0.01). The total effective rate of the observation group was 93.18%, which was significantly higher than that of the control group (88.63%, P <0.05). There was no significant difference between the two groups in the incidence of adverse drug reactions (P> 0.05). Conclusion: The efficacy of edaravone combined with norepinephrine in the treatment of acute cerebral infarction is better than that of edaravone alone, which may improve the prognosis of patients and deserve clinical promotion.